EXOME: Biotech • Healthcare • Life Sciences

Boston
Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing

National
The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination Period
National
Novavax Gets $1.6B in Operation Warp Speed Funding for COVID-19 Vaccine
Boston
Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs

1.
Sanofi Pays Kymera $150M to Kick Off Protein Degrader Partnership | Boston
2.
NFlection Looks to Erase NF1 Tumors With Drug That Only Goes Skin Deep | Philadelphia
3.
VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs | San Diego
4.
Biogen Alzheimer’s Drug in FDA’s Court Following Completion of Filing | Boston
5.
The 2020 National Xconomy Awards Expands, Goes Virtual & Reopens Nomination Period | National
6.
Foghorn Therapeutics Inks Chromatin-Targeting Cancer Deal with Merck | Boston

Learn about the Xconomists →

Alexis Peyroles

Creating Consistent Value in Biotech Without Diluting Stakeholders

Andy Smith

Lax Approval Requirements Yield Blockbusters That Don’t Work

More Opinion, Insight, and Analysis ›

Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing

$137M

VelosBio

Cend Therapeutics Names Viracta’s David Slack As Its New President & CEO

Kinnate Adds WuXi NextCODE’s Richard Williams as Chief Medical Officer

Novavax Gets $1.6B in Operation Warp Speed Funding for COVID-19 Vaccine
Sarah de Crescenzo | National
Vor Nabs $110M to Spare Healthy Cells From Targeted Cancer Drugs
Sarah de Crescenzo | Boston
PacBio CEO, CFO Plan Retirements and More People on the Move
Editors | National
On Heels of $100M Financing, Annexon Bio Aims to Tack On More Via IPO
Sarah de Crescenzo | San Francisco
Bristol Myers Pays Dragonfly $55M to Bring NK Cells to Neuro Diseases
Frank Vinluan | Boston
MEI Pharma, Helsinn Scuttle Cancer Drug Trial After Miss on Efficacy
Sarah de Crescenzo | San Diego
Moderna: Speed of COVID 19 Vaccine Hinges On Enrolling Right Patients
Sarah Karlin-Smith | National
Data Quantity, Complexity Drives Use of AI in Drug Discovery and Testing
Frank Vinluan | San Francisco
Annexon Adds On $100M to Advance Antibodies to Treat Neurodegeneration
Sarah de Crescenzo | San Francisco

Read More Posts ›

Underwriters and Partners

Xconomy Insight

Sponsored · Whitepaper
What’s Next in Neuroscience Therapies
New approaches & tech are on the horizon that could change how researchers and clinicians approach brain and neurological disorders

Sponsored · Special Report
As the Commercial Real Estate Market Slumps, Look for a More Tenant-Friendly Future
Hyperinflation in rents is over
Hughes Marino

Sponsored · Whitepaper
COVID-19 Special Report: Sustaining Clinical Research During the Crisis
Leveraging technology & expertise to ensure a continual journey from trials to treatments
PRA Health Sciences

Xconomy on Demand

We offer a number of ways to subscribe for free!